

GC–MS Analysis of Ethanol Root Extract of Datura stramonium

I.E. Otuokere¹, O.V. Ikpeazu² and K.K. Igwe³

 Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria
 Department of Biochemistry, Abia State University, Uturu, Nigeria
 Department of Vet. Biochemistry and Animal Production, Michael Okpara University of Agriculture, Umudike, Nigeria
 Corresponding author: I.E. Otuokere

Date of Submission: 15-07-2020

Date of Acceptance: 31-07-2020

ABSTRACT:Identification of the phyto constituents present in the ethanolic root extract of D. stramonium. The structural formula of the phytochemicals of D. stramonium root extract were determined by analysing of the spectra of GC-MS using the reference standard of National Institute of Standard and Technology (NIST). GC-MS analysis of D. stramonium root showed the presence of nineteen bioactive compounds. The compounds are Eburnamenin-14-ol, 14,15-dihydro-,(14);2,3-dihydro-1H-cyclopenta[4,5]pyrimido[1,2a]benzimidazol-11-ol; bis[4-[m-hydroxyanilino]-3nitrophenyl]sulfone; acetamide, 2,2,2-trifluoro; 3,3dimethoxycarbonyl-cis-(2,2')(5,5')pyridinophane; butylphosphonic acid, 2,6-dimethoxyphenyl nonyl ester; iso-Valeraldehyde propyleneglycol acetal; iso-Valeraldehyde propyleneglycol acetal; 11oxatetracyclo[6.2.1.0(2,7).0(3,6)]undec-9-ene, 2,3,4,4,5,5,6,7-octafluoro; (E)-1-methylsulfinyl-2phenylethene; isovaline, 3-hydroxy; valeric acid, 2diethylaminoethyl ester; N-(2-nitro)benzylidene-2-(4-methylphenylthio)aniline; mitragynine; methyl 3'.27-dihydroxyolean-12-en-28-oate; 4Hnaphtho[2,3-b]pyran-4-one, 5,10-bis(acetyloxy)-2,3-dihydro-3-hydroxy-2-methyl-, trans; trans-2,3-

Bis(2,4,5-trimethyl-3-thienyl)-2,3-dihydrofuro[2,3-f][4,7]phenanthroline;3,8-dioxa-11-

azatetracyclo[4.4.1.0 (2,4).0(7,9)] undecane, 11-(phenylsulfonyl)-, $(1',2',4',6',7(,9\beta)$; phenol, 2,2'-[(hydroxyimino)bis(4,5-dihydro-5,3-

isoxazolediyl)]bis. It was concluded that the bioactive compounds support the use of D. *stramonium* root for the management of breast cancer, cancer of the esophagus, anaphylaxis and Parkinson's disease.

KEYWORDS: Bioactivity, *D. stramonium*, ethanol, gas chromatography, mass spectra, plant,

I. INTRODUCTION

D. stramonium is an annual, erect, branching herb with a foul-smell. It forms a bush up to 60 to 150 cm (2 to 5 ft) height [1]. It has a white fibrous long thick root while the stem is leafy with a yellow-green to reddish purple color [2]. The leaves of *D. stramonium* are long, smooth, toothed, soft and irregularly undulated with a length of about 8 to 20 cm (3–8 in) [2]. The upper surface of the leaves are dark green, while the bottom is light green in colour [1]. The leaves taste bitter and nauseating. The bitter and nauseating taste remains even after drying and extraction [2].

The active agent in D. stramonium is atropine. Atropine has been used in herbal medicine and recreational activities over the years [3]. Generally, the leaves are smoked either in a cigarette or in a pipe [4,5]. D. stramonium are used as analgesic to render patients unconscious while broken bones were healed [6]. The Asians used it as a form of anesthesia during surgical operations [7]. D. stromonium is culturally used in management of inflammation. Gupta and Coworkers [8] subjects ethanol extract of D leaves preliminary stromonium to antiinflammatory activity screening in albino rats. They reported that ethanol extracts of D. stromonium leaves exhibited significant antiinflammatory activity against carrageenan induced rat paw edema when compared to diclofenac [8]

Many authors have reported the GC-MS analysis of plant extract [9-11]. In our previous publication we reported the GC-MS analysis of *D*. *stromonium* ethanol leave extract [12]. To the best of our knowledge, the GC-MS analysis of *D*. *stromonium* ethanol root extract has not been reported in literature. Biological active phytocomponents present in the leaves of *D*. *stromonium* root is hereby studied for future



reference studies. This study is aimed at the determination of compounds present in *D. stromonium* ethanol root extract by GC–MS analysis.

II. EXPERIMENTATION

a) Plant sample

Fresh *D. stromonium* root were harvested from Ohafia, Abia State Nigeria on 25th June, 2020. The leaves were identified by a Botanist at the Department of Plant Science and Biotechnology, MOUAU, Nigeria.

b) Extraction of crude extracts

The *D. stromonium* root were air dried at room temperature for 3 days. The dried roots were grounded using electric grinder. The powdered *D. stromonium* root were subjected to extraction using ethanol. The extract was then subjected to evaporation by using rotary evaporator.


c) GC-MS Analysis

The GC–MS spectra of bioactive compounds of *D. stromonium* root extracts were analysed using agilent 6890N gas chromatography

equipped with an auto sampler connected to an agilent Mass Spectrophotometric Detector . A micro-litre of sample was injected in the pulsed spitless mode onto a 30m x 0.25 mm ID DB 5MS coated fused silica column with a film thickness of 0.15 micrometer. Helium gas was used as a carrier gas and the pressure of the column head was maintained at 20 psi to give a constant of 1ml/min. The temperature of the column was held initially at 55 °C for 0.4 min and then raised to 200 °C at a rate of 25 °C/mins,. It was increased to 280 °C at a rate of 8 °C/mins and to a final temperature of 300 °C at a rate of 25 °C/mins for 2 mins . The identification time was based on retention time. Components with lower retention time eluted first before the ones of higher retention time.

d) Identification of chemical constituents


The structural formula of the compounds present in ethanol extract of *D. stromonium* root were ascertained by the interpretation of mass spectrum of GC-MS using the reference standard of NIST library. The mass spectra of the unknown compounds were cross-marched with the spectra of the known compounds stored in the NIST library.




III. RESULTS AND DISCUSSION

Figure 1: Gas chromatogram of *D. stromonium* ethanol root extract























International Journal of Advances in Engineering and Management (IJAEM)Volume 2, Issue 3, pp: 243-253www.ijaem.netISSN: 2395-5252












Figure 2: Mass spectra bioactive compounds present in ethanol extract of *D. stranonium* root

S/No	Compound	Bioactivity
1	Eburnamenin-14-ol, 14,15-dihydro-, (14)	Oligosaccharide Provider
2	2,3-Dihydro-1H-cyclopenta[4,5]pyrimido[1,2- a]benzimidazol-11-ol	Not found
3	Bis[4-[m-hydroxyanilino]-3-nitrophenyl]sulfone	Not found
4	Acetamide, 2,2,2-trifluoro	Not found
5	3,3-Dimethoxycarbonyl-cis-(2,2')(5,5')pyridinophane	Not found
6	Butylphosphonic acid, 2,6-dimethoxyphenyl nonyl ester	Increase Aromatic Amino Acid Decarboxylase Activity, Arachidonic acid-Inhibitor
7	Iso-Valeraldehyde propyleneglycol acetal	Not found
8	Iso-Valeraldehyde propyleneglycol acetal	Not found
9	11-Oxatetracyclo[6.2.1.0(2,7).0(3,6)]undec-9-ene, 2,3,4,4,5,5,6,7-octafluoro	Not found
10	(E)-1-Methylsulfinyl-2-phenylethene	Anticancer (Esophagus)
11	Isovaline, 3-hydroxy	17-beta-hydroxysteroid dehydrogenase-Inhibitor
12	Valeric acid, 2-diethylaminoethyl ester	Increase Aromatic Amino Acid Decarboxylase Activity, Arachidonic acid-Inhibitor
13	N-(2-Nitro)benzylidene-2-(4-methylphenylthio)aniline	Anaphylactic (antidote)
14	Mitragynine	Not found
15	Methyl 3',27-dihydroxyolean-12-en-28-oate	Catechol-O-Methyltransferase- Inhibitor, Methyl-Guanidine- Inhibitor
16	4H-Naphtho[2,3-b]pyran-4-one, 5,10-bis(acetyloxy)-2,3- dihydro-3-hydroxy-2-methyl-, trans	Not found
17	trans-2,3-Bis(2,4,5-trimethyl-3-thienyl)-2,3- dihydrofuro[2,3-f][4,7]phenanthroline	Not found
18	3,8-Dioxa-11-azatetracyclo[4.4.1.0(2,4).0(7,9)]undecane, 11-(phenylsulfonyl)-, (1',2',4',6',7(,9β)	Not found
19	Phenol, 2,2'-[(hydroxyimino)bis(4,5-dihydro-5,3- isoxazolediyl)]bis	Not found



Bioactive compounds present in ethanol extract of *D. stranonium* root have been presented in Table 1. *D. stranonium* root have been reported as oligosaccharide provider, aromatic amino acid decarboxylase activity inducer, arachidonic acidinhibitor, anticancer (esophagus), 17-betahydroxysteroiddehydrogenaseinhibitor, anaphylacti c(antidote), catechol-O-methyltransferase-inhibitor, methyl-guanidine-inhibitor [13].

An oligosaccharide is a saccharide polymer that consist of three to ten monosaccharides. Oligosaccharides have numerous functions such as cell recognition and cell binding [14]. A typical example of oligosaccharide cell recognition is the role of glycolipids in determining blood types. Glycolipids also play vital role in the immune response [15].

Among all endocrine therapies for the treatment of breast cancer, inhibition of estrogen biosynthesis is becoming an interesting complementary approach to the use of antiestrogens. The enzyme 17-beta-hydroxysteroid dehydrogenase-Inhibitor (17beta-HSD) plays a critical role in the biosynthesis of estradiol catalyzing preferentially the reduction of estrone estradiol. the most active into estrogen. Consequently, this enzyme is an interesting biological target for designing drugs for the treatment of estrogen-sensitive diseases such as breast cancer [16].

Aromatic L-amino acid decarboxylase (AAAD) was discovered 70 years ago in mammalian tissue [17]. Its specific importance in pharmacology was established when it was demonstrated that its substrate L- DOPA relieved the clinical symptoms of Parkinson's disease (PD) [18-20] by supplementing lost dopamine from nigrostriatal neurons.

Catechol-O-methyltransferase inhibitors are category of medicines that are used along side carbidopa-levodopa therapy in the management of symptoms of Parkinson's disease. Catechol-Omethyltransferase inhibitors can extend the effectiveness of carbidopa-levodopa therapy, and permit for lower doses of carbidopa-levodopa [22].

Arachidonic acid and its metabolites have recently generated a heightened interest because of growing evidence of their significant role in cancer biology. Thus, inhibitors of arachidonic acid have originally been of interest in the management of inflammatory disorders and certain types of heart disease. They are now receiving increased attention as an arsenal against cancer [23].

Methylguanidine is a suspected uraemic toxin that accumulates in kidney failure; however it also exhibits anti-inflammatory effects. Recent evidence suggests that methylguanidine significantly inhibits nitric oxide synthase activity and tumor-necrosis factor (TNF) release [24]. This suggests that methylguandine can attenuate the degree of inflammation and tissue damage related to endotoxic shock.

IV. CONCLUSION

Nineteen compounds have been identified from the GC-MS analysis of ethanol extracts of *D*. *stranonium* root. The bioactive compounds support its use in the management of diseases like breast cancer, cancer of the esophagus, anaphylaxis and Parkinson's disease.

REFERENCES

- Henkel, A. 1911. "Jimson weed". American Medicinal Leaves and Herbs. U.S. Government Printing Office. p. 30.
- [2]. Grieve, M. 1971. A Modern Herbal: The Medicinal, Culinary, Cosmetic and Economic Properties, Cultivation and Folklore of Herbs, Grasses, Fungi, Shrubs, & Trees with All Their Modern Scientific Uses, Volume 2. Dover Publications. p. 804.
- [3]. Glatstein, M., Alabdulrazzaq, F., Scolnik, D. 2016. "Belladonna Alkaloid Intoxication". American Journal of Therapeutics. 23 (1): e74–e77.

doi:10.1097/01.mjt.0000433940.91996.16.

- [4]. Barceloux, D. G. 2008. "Cáscara". Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals. John Wiley & Sons. p. 1877.
- [5]. Pennachio, M. 2010. Uses and Abuses of Plant-Derived Smoke: Its Ethnobotany As Hallucinogen, Perfume, Incense, and Medicine. Oxford University Press. p. 6.
- [6]. Turner, M. W. 2009. Remarkable Plants of Texas: Uncommon Accounts of Our Common Natives. University of Texas Press. p. 209.
- [7]. Nellis, D. W. 1997. Poisonous Plants and Animals of Florida and the Caribbean. Pineapple Press. p. 238.
- [8]. Gupta S, Raghuvanshi M, Jain D.2010. Comparative studies onanti-inflammatory activity of Coriandrum Sativum, Datura stramonium and Azadirachta Indica. Asian J Exp Biol Sci., 1(1): 151-154.
- [9]. Igwe, K.K., Nwankwo, P.O., Otuokere, I.E., Chika, I. and Amaku, F.J. 2016. Studies on the medicinal plant Acalypha wilkesiana ethanol extracts phytocomponents by GC-MS analysis,

DOI: 10.35629/5252-0203243253 | Impact Factor value 7.429 | ISO 9001: 2008 Certified Journal Page 252



Global Journal of Science Frontier Research, Vol. 16(2): 48–55.

- [10]. Ikpeazu, O.V., Otuokere, I.E. and Igwe, K.K. 2020. GC–MS Analysis of Bioactive Compounds Present in Ethanol Extract of *Combretum hispidum* (Laws) (Combretaceae) leaves, International Journal of Trend in Scientific Research and Development, Vol. 4(5): 307 - 313
- [11]. Otuokere, I.E., Okorie, D.O., Igwe K.K. and Mathew. U.J. 2016. GCMS Determinatiopn of Bioactive Phytocompounds in *Chromolaena odorata* leaf exract. Int J of Advances in Engineering Tech and Sci. Vol. 2(3): 7-11.
- [12]. Otuokere, I.E., Igwe K. K. and Ikpeazu. O.V. 2020. GC–MS analysis of phytochemicals present in ethanol extract of *Datura stramonium* leaves, International Research Journal of Modernization in Engineering, Technology and Science, 2(7): 869 - 876
- [13]. Duke, J.A. 1992. Handbook of phytochemical constituents of GRAS herbs and other economic plants. Boca Raton, FL. CRC Press.
- [14]. Alberts, B., Johnson, A., Lewis, J. 2002."Molecular Biology of the Cell. 4th edition".New York: Garland Science; Retrieved 16 August 2018.
- [15]. Kailemia, M.J., Ruhaak, L.R., Lebrilla, C.B. Amster, I.J. 2014. "Oligosaccharide analysis by mass spectrometry: a review of recent developments". Analytical Chemistry. 86 (1): 196–212. doi:10.1021/ac403969n.
- [16]. Martin, R. T., Roch, P. B., Van Luu-The, D.P.2005. Inhibitors of Type 1 17beta hydroxysteroid Dehydrogenase With Reduced EstrogenicActivity: Modifications of the Positions 3and 6 of Estradiol, Journal

of Enzyme Inhibition and Medicinal Chemistry, 20, 2: 153 -163.

- [17]. Holtz, P., Heise, R. and Ludtke, K. (1938).
 Fermentativer Abbau von L-Dioxyphenylalanin (Dopa) durch Niere.
 Naunyn Schmiedeberg's Arch exp Path Pharmak. Vol. 191, 87–118.
- [18]. Birkmayer, W. and Hornykiewicz, O. (1961). The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.. Wien Klin Wochenschr, Vol. 73, 787–788.
- [19]. Cotzias, G.C., Van Woert, M.H. and Schiffe, L.M. (1967). Aromatic amino acids and modification of Parkinsonism. N Engl J Med, Vol. 276, 374–379.
- [20]. Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E. and Hoehn, M.M.(1969) Treatment of Parkinsonism with levodopa. Arch Neurol, Vol. 21, 343–354.
- [21]. Duke, J.A. (1992). Handbook of phytochemical constituents of GRAS herbs and other economic plants. Boca Raton, FL. CRC Press.
- [22]. Connolly, B.S. and Lang. A.E.(2014). Pharmacological treatment of Parkinson disease: a Review. JAMA. Vol. 311(16) pp. 1670-1683.
- [23]. Hyde, C.A.C. and Missailidis, S. 92009). Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis, International Immunopharmacology, Vol. 9 (6), 701-715.
- [24]. National library of Medicine (2020). National Center for Biotechnology Information. PubChem Database, Methylguanidine. Available at https://pubchem.ncbi.nlm.nih.gov/compound /methylguanidine